- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How the Genetic Nature of Lp(a) Levels Influences Screening
Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.
EP: 1.Lp(a) in ASCVD and Guideline Recommendations
EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening
EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing
EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake
EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience
EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models
EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management
Video content above is prompted by the following:
- I mentioned in the introduction that a person’s Lp(a) levels are mostly determined by genetics. What evidence supports this conclusion?
- How might the hereditary nature of Lp(a) help drive awareness of risk for ASCVD and aortic stenosis and influence screening protocols?
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Effect of Remote Patient Monitoring on Stage 2 Hypertension
May 6th 2025A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.
Read More
